ObsEva, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva’s Executive Committee, effective May 10, 2021. Wim Souverijns has served as Chief Commercial Officer of ObsEva since November 2018 and will leave the Company on June 30, 2021 to pursue a new opportunity. He will work to ensure a smooth transition with Clive Bertram.
“We are delighted to welcome Clive to the executive team, especially at such an exciting time for the Company,” said Brian O’Callaghan, Chief Executive Officer of ObsEva. “Clive has a demonstrated track record of leadership and I am confident he will play a key role in further strengthening our relationships with investors and potential partners as we become a commercial company and prepare for the launch of Yselty in Europe, as well as the filing of a new drug application in the U.S. for the treatment of heavy menstrual bleeding and pain associated with uterine fibroids in pre-menopausal women. On behalf of the Board of Directors and Executive team, I would also like to thank Wim Souverijns for his leadership and contributions to the Company during his two plus year tenure at ObsEva.”
Clive Bertram joins ObsEva with nearly 30 years of experience in commercialization, strategic, corporate and business development in the pharmaceutical industry. Most recently, he served as Chief Commercial Officer at Petra Pharma and Sangart. Clive also served as an independent consultant leading client thinking for strategic and marketing planning insight as well as launch excellence and implementation. Prior to his Chief Commercial Officer roles, Clive held senior management positions at Pharmion Limited, Chiron Biopharmaceuticals, Celltech and Eli Lilly. He holds a Bachelor of Science in Pharmacology & Chemistry from the University of Sheffield and will operate out of the UK.
“I am excited to be joining as Chief Commercial Officer at such an important time for the Company, as we prepare for the launch of its lead product, Yselty, for uterine fibroids, in Europe and subsequently the U.S., and plan for future commercialization. I look forward to working with the team on this exciting journey,” said Clive Bertram.
